Talis Biomedical Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Rob Kelley
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 54.1% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.04% |
| Management average tenure | no data |
| Board average tenure | 2.9yrs |
Recent management updates
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$57m |
| Dec 31 2023 | US$1m | US$551k | -US$62m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$86m |
| Mar 31 2023 | n/a | n/a | -US$98m |
| Dec 31 2022 | US$2m | US$525k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$127m |
| Mar 31 2022 | n/a | n/a | -US$165m |
| Dec 31 2021 | US$2m | US$322k | -US$192m |
| Sep 30 2021 | n/a | n/a | -US$208m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$2m | US$89k | -US$91m |
Compensation vs Market: Rob's total compensation ($USD1.02M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
CEO
Rob Kelley (52 yo)
2.9yrs
Tenure
US$1,019,331
Compensation
Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | US$1.02m | 0.037% $ 1.2k | |
| Lead Independent Director | 2.9yrs | US$117.10k | 0.76% $ 23.4k | |
| Independent Director | 8.8yrs | US$100.27k | 6.3% $ 194.2k |
2.9yrs
Average Tenure
65yo
Average Age
Experienced Board: TLIS's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.